Abstract
Drug repurposing presents a potential solution for finding new therapies for rare and orphan diseases. The limited number of patients affected by rare diseases, combined with scarce research and the financial burden of clinical trials, creates a significant barrier to developing new drugs. Drug repurposing utilizes the known safety profile and effectiveness of existing medications to fast-track the development of life-saving therapies.
Recently drug repurposing has focused on utilizing biomedical knowledge graphs to uncover hidden connections between diseases and drugs, revealing promising candidates for repurposing. Because most knowledge graphs in biomedical domain are made by text-mining scientific literature we decided to compare the amount of knowledge contained in open access and controlled (subscription only) access literature.
Elsevier and Every Cure make logical partners and allowed the project to use Elsevier’s ability to access both controlled and open access publications and its proprietary Elsevier AI technology to construct the knowledge graph. Notwithstanding the fact that more than 50% of relationships in drug repurposing for rare diseases can be found in open access content, 45% of relationships remain only in controlled access. We argue that this is due to the large number of edges supported by single reference in the entire biomedical knowledge graph and does not reflect an intrinsic difference between open and controlled access.
Competing Interest Statement
One author (A. Yuryev) is employee of Elsevier Ltd. Dr Grant Mitchell has also collaborated with Elsevier.
Funding Statement
This study did not receive any funding except support from the organisations listed in the author affiliations
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
One author asked to remove herself. Additional spellchecking was done using MS Word.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- EBKG
- Elsevier Biology Knowledge Graph
- OA
- Open Access
- CA
- Controlled Access
